Why Cancer Patients And Doctors Should Rethink The Value Of Phase 1 Trials

640x0

CANCER PATIENTS – of all the reports being presented at this year’s big cancer meeting, the one I think most important is not about a particular drug or malignancy. It’s about the design of clinical trials.

For cancer patients trying an experimental drug, participating in a “matched” study–using biomarkers, like genetics, to link their condition to a treatment–offers much greater chances of clinical benefit than does participating in a similar, unmatched study. The abstract*, authored by a geographically wide research group, will be delivered in Chicago by Maria Schwaederlé, PharmD, of the University of California in San Diego.

Read more here


Leave a Reply

Your email address will not be published. Required fields are marked *


Home / Cancer Right / Why Cancer Patients And Doctors Should Rethink The Value Of Phase 1 Trials